KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to $252.3 million.

  • Supernus Pharmaceuticals' Operating Expenses rose 8713.03% to $252.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $718.5 million, marking a year-over-year increase of 2122.01%. This contributed to the annual value of $580.2 million for FY2024, which is 532.63% down from last year.
  • As of Q3 2025, Supernus Pharmaceuticals' Operating Expenses stood at $252.3 million, which was up 8713.03% from $153.3 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' Operating Expenses' 5-year high stood at $252.3 million during Q3 2025, with a 5-year trough of $107.2 million in Q2 2021.
  • In the last 5 years, Supernus Pharmaceuticals' Operating Expenses had a median value of $150.5 million in 2022 and averaged $151.2 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first crashed by 1852.34% in 2023, then soared by 8713.03% in 2025.
  • Supernus Pharmaceuticals' Operating Expenses (Quarter) stood at $153.0 million in 2021, then dropped by 13.05% to $133.0 million in 2022, then grew by 24.3% to $165.3 million in 2023, then fell by 7.6% to $152.8 million in 2024, then surged by 65.19% to $252.3 million in 2025.
  • Its Operating Expenses stands at $252.3 million for Q3 2025, versus $153.3 million for Q2 2025 and $160.1 million for Q1 2025.